Browsing Tag
Cantor Fitzgerald
16 posts
Nuvectis Pharma just raised $100 million, so why are NVCT shareholders selling?
Nuvectis Pharma shares fell 19% after a $100 million offering priced at $20. Read what dilution, runway and pipeline expansion mean for NVCT investors now!
uniQure surges 78% as FDA clears accelerated approval path for its Huntington’s disease gene therapy
uniQure (QURE) surges 78 percent as FDA clears accelerated approval path for AMT-130 in Huntington's disease, with BLA filing due Q3 2026. Full analysis.
uniQure (QURE, NASDAQ) targets Q3 BLA after FDA’s Huntington’s reversal
The FDA spent months blocking uniQure's Huntington's gene therapy. Now it wants the filing in Q3. QURE doubled, but approval is still unwon.
Intuitive Machines (NASDAQ: LUNR) surges 11% on Cantor upgrade and Lunar Terrain Vehicle catalyst
Intuitive Machines ran 80% on a Cantor upgrade and a pending NASA contract. But the rover award just went to rivals, and the stock trades at 39x sales.
HubSpot (NYSE: HUBS) rebounds from the AI pricing reset as retail bets on a Q2 turnaround
HubSpot beat on every Q1 line and still lost a fifth of its market cap in a week. The real question is whether AI pricing fixes the moat or breaks the model.
Insmed (NASDAQ: INSM) rebounds as retail eyes ATS 2026 readouts after Q1 reset
INSM bounced 11% after a 20% post-earnings reset. BRINSUPRI is launching faster than any respiratory drug in a decade. So why did the market sell the print?
European Lithium (ASX: EUR) share price gains 5% as Critical Metals merger nears 7 May binding agreement
Critical Metals offered A$0.58 per EUR share. Thursday is the binding deadline. A $24m cash shortfall and Tanbreez consolidation are the live tensions.
Critical Metals Corp (NASDAQ: CRML) to acquire European Lithium in $835m rare earth play
Critical Metals Corp is paying $835M to buy its own 34% shareholder. The real prize is uncontested control of Greenland's Tanbreez rare earth deposit.
OMEX surges 90% as Odyssey Marine Exploration agrees to merge with American Ocean Minerals
American Ocean Minerals and Odyssey Marine Exploration agree to $1B merger targeting deep-sea polymetallic nodules. What it means for U.S. critical minerals. Read more.
VERAXA Biotech clears final shareholder hurdle as Voyager Acquisition votes yes on $1.35bn oncology de-SPAC
Voyager Acquisition shareholders approve VERAXA Biotech combination. The cancer ADC and TCE platform heads to NASDAQ as VRXA. Read the full analysis.